BioLamina

Penny Paucek PhD

🇬🇧 United Kingdom

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Adam Leannon-Huels DVM

🇷🇺 Russia

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Rosemary Crist

🇷🇺 Russia

9.4

Reviewed: November 8, 2023

• - Health Technology Assessment
• - 10 weeks September - November 2023
• - Pharmaceutical Company

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Jon Stehr

🇯🇵 Japan

9.3

Reviewed: September 14, 2023

• - Project Management
• - 10 weeks July - September 2023
• - Biotech Company

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Donna Schimmel

🇮🇳 India

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.

Norman Mertz

🇹🇷 Turkey

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Mrs. Diana Sipes

🇺🇸 United States

8.8

Reviewed: May 15, 2024

• - Companion Diagnostics Development
• - 16 weeks January - May 2024
• - Pharmaceutical Company

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.